丙利酸钾 | 49847-97-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 丙利酸钾
• CAS: 49847-97-4
• 化学式: C23H32KO4
• 分子量: 411.6
• InChiKey: SXOJVLBEGBHTRW-CZKUEYQYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.59
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Aldosterone-antagonistic steroids
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0115273A2

  公开（公告）日：1984-08-08

  Novel spironolactone derivatives characterized by the C11 - C12 double bond which have a potent aldosterone-antagonistic activity without causing potassium loss, used alone in diagnosis and improvement of condition of primary aldosteronism, or together with other drugs in treatment of essential or renal hypertension as well as cardiac or renal edema; prepared from 3,17-bis (ethylene-dioxy)-5,11- androstadiene.

  新型螺内酯衍生物，其特点是具有 C11 - C12 双键，具有强效的醛固酮拮抗活性，不会导致钾流失，可单独用于诊断和改善原发性醛固酮增多症，或与其他药物一起用于治疗原发性或肾性高血压以及心脏或肾脏水肿；由 3,17-双（乙烯二氧）-5,11-雄甾二烯制备而成。
• Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0129284A2

  公开（公告）日：1984-12-27

  Improved topical pharmaceutical compositions containing a pharmaceutically-active agent and the penetration enhancing agent 1-dodecylazacycloheptan-2-one are disclosed. This agent is used at selected levels in combination with certain C3-C4 diols or a 1-substituted azacycloalkyl-2-one. This composition provides marked transepidermal and percutaneous delivery of the selected pharmaceutically-active agent. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

  本发明公开了含有一种药物活性剂和渗透增强剂 1-十二烷基氮杂环庚烷-2-酮的改良外用药物组合物。这种药剂与某些 C3-C4 二醇或 1-取代偶氮环烷基-2-酮结合使用时，可达到选定的水平。这种组合物能明显地经皮和经皮给药。此外，还公开了一种全身或局部治疗对所选活性剂有反应的某些病理和病症的方法。
• Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0129285A2

  公开（公告）日：1984-12-27

  Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration-enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and percutaneous delivery of the active selected. A method of treating certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed.

  本发明公开了一种外用药物组合物，该组合物包含一种药物活性剂和一种新型的渗透增强载体或载体。载体或载体包括 N-（2-羟乙基）吡咯烷酮和 "细胞包膜紊乱化合物 "的二元组合。这些组合物能明显地经皮和经皮递送所选的活性物质。此外，还公开了一种全身或局部治疗对所选活性物质有反应的某些病理和病症的方法。
• EP0129285B1
  申请人：——

  公开号：EP0129285B1

  公开（公告）日：1991-05-15
• ANTI MINERALOCORTICOID THERAPY OF INFECTION
  申请人：Prendergast, Patrick T.

  公开号：EP1940414A2

  公开（公告）日：2008-07-09